DIRS.INFO The most relevant business & tech news

☆ Cramer's Lightning Round: Do not sell Constellation Energy
▼ + stars: | 2024-07-29 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Illumina's year-to-date stock performance. Stock Chart Icon Stock chart icon Bank of America's year-to-date stock performance. Stock Chart Icon Stock chart icon Constellation Energy's year-to-date stock performance. Stock Chart Icon Stock chart icon Meta's year-to-date stock performance. Stock Chart Icon Stock chart icon Organon's year-to-date stock performance.

Persons: one's, Jim Cramer's Organizations: of America's, Bank of America, Constellation Energy, ICICI, ICICI Bank, Pfizer, Organon Locations: India

☆ Stocks making the biggest moves midday: Intuit, AMD, LegalZoom.com, Baidu and more
▼ + stars: | 2024-07-10 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

In terms of revenue, LegalZoom now expects between $675 million and $685 million for the full year. Taiwan Semiconductor Manufacturing — The chip stock advanced 3% following the company's revenue results . Though the company's reported T$207.87 billion for the month of June was a 9.5% decrease from last month, it was a 32.9% increase from the year-ago period. For January through June this year, the company reported T$1.27 trillion, which is a 28% increase from the same period last year. Carvana — Shares of the online car seller added 5% after Needham upgraded the stock to buy from hold.

Persons: LegalZoom.com, Dan Wernikoff, Jeffrey Stibel, LegalZoom, Carvana, Needham, robotaxi, —, Alex Harring, Fred Imbert, Samantha Subin, Pia Singh, Michelle Fox, Darla Mercado Organizations: Intuit —, Intuit, Taiwan Semiconductor Manufacturing, Baidu, Street Journal, Shanghai, Mastercard, Visa, Bank of America, Manchester United, BioSciences, Analysts, Illumina, Teva Pharmaceutical Industries, Argus, UBS, Science, AMD, Silo Locations: China, Shanghai, Hoka, Europe

☆ Cramer's Lightning Round: 'Stay away' from Delta
▼ + stars: | 2024-01-23 | by ( Julie Coleman | ) www.cnbc.com time to read: 1 min

Stock Chart Icon Stock chart icon Fluor's year-to-date stock performance. Stock Chart Icon Stock chart icon Illumina's year-to-date stock performance. Stock Chart Icon Stock chart icon Delta's year-to-date stock performance. People should understand airlines are trades...I say stay away." Stock Chart Icon Stock chart icon Ferrari's year-to-date stock performance.

Persons: they've Organizations: Ferrari Locations: Delta

☆ Stocks making the biggest moves premarket: Plug Power, Illumina, Diageo and more
▼ + stars: | 2023-11-10 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Wynn notched an adjusted 99 cents per share on $1.67 billion in revenue, while analysts polled by LSEG forecast 75 cents and $1.59 billion. Illumina's revenue was lower than analysts' estimates, although the company had beat on adjusted earnings per share in the third quarter. After the closing bell Thursday, Plug Power had reported a surprisingly larger loss for the third quarter along with disappointing revenue. TKO Group — The stock tumbled 7.5% after Executive Chairman Vince McMahon said he planned to sell 8.4 million shares of the WWE parent company. The company posted third-quarter adjusted earnings and revenue that exceeded estimates, however.

Persons: Wynn, Vince McMahon, LSEG, —, Alex Harring, Tanaya Macheel, Brian Evans Organizations: Wynn Resorts, LSEG, Wynn, Diageo —, RBC Capital Markets, WWE, McMahon, Capri Locations: Wynn Macau, America, Caribbean

☆ Stocks making the biggest moves midday: Groupon, Wynn Resorts, Plug Power, Illumina and more
▼ + stars: | 2023-11-10 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

Wynn Resorts — The resort-and-casino stock dropped 7.3% as analysts focused on EBITDAR, which includes restructuring, tied to its operations in Macao. Plug Power — Shares of the clean energy company tumbled more than 34%, reaching a new 52-week low, after third-quarter earnings and revenue missed analysts' estimates. TKO Group — The WWE parent slid 7.9% after Executive Chairman Vince McMahon said he planned to sell 8.4 million shares. Treace Medical Concepts — Shares tumbled 40% after the medical device company missed third-quarter expectations and lowered its full-year revenue guidance. The company also cut revenue guidance for the year.

Persons: Vince McMahon, Treace, Freyr, Wells, Synaptics, LSEG, Vera Therapeutics, Vera, —, Sarah Min, Hakyung Kim, Pia Singh Organizations: Wynn Resorts, Diageo —, Diageo, RBC, JPMorgan, WWE, Wall, Analysts, Jefferies Locations: billings, Macao, America, Caribbean, Wells Fargo, Hawaii

☆ Cramer's Lightning Round: Yes to St. Joe
▼ + stars: | 2023-09-13 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon RTX's year-to-date stock performance. Stock Chart Icon Stock chart icon St. Joe's year-to-date stock performance. St. Joe : "I've liked St. Joe forever...I'm going to say yes to that one." Stock Chart Icon Stock chart icon Illumina's year-to-date stock performance. Stock Chart Icon Stock chart icon Cava's year-to-date stock performance.

Persons: Joe, I've, Jim Cramer's Organizations: Parts, Charitable Locations: Joe's, Cava

☆ Carl Icahn says new Illumina CEO has his 'full support' months after proxy fight
▼ + stars: | 2023-09-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Carl Icahn on Thursday expressed his support for Illumina 's new CEO Jacob Thaysen – a relief for the company as it tries to rebound from a bitter proxy fight with the billionaire activist investor. "I think he will do an excellent job and he has my full support," Icahn said in a post on X, noting that he spoke with Thaysen. Icahn, who continues to own a small stake in Illumina, launched a proxy battle over the company's decision to close its $7.1 billion acquisition of cancer test developer Grail in 2021 without approval from antitrust regulators in U.S. and European Union. Icahn was a staunch critic of Illumina's former CEO Francis deSouza, who ultimately resigned after the proxy battle in May despite securing enough votes to stay. "I'd find it comical, if it wasn't so reprehensible that ILMN's share price is down 63% due to CEO Francis deSouza making such an absurd and questionable purchase," Icahn said in a statement to CNBC in March.

Persons: Carl Icahn, Jacob Thaysen –, Icahn, Thaysen, Francis deSouza Organizations: Union, CNBC Locations: Illumina

☆ Illumina names new CEO months after Icahn proxy fight over Grail deal
▼ + stars: | 2023-09-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Illumina 's board on Tuesday named Jacob Thaysen the DNA sequencing company's new CEO as it tries to rebound from a grinding dispute over its acquisition of cancer test developer Grail. Thaysen, a 48-year-old longtime executive at medical devices firm Agilent , will step in as CEO on Sept. 25. His nomination comes months after a bitter proxy fight with activist investor Carl Icahn ended with Illumina's former CEO Francis deSouza resigning despite securing enough votes to stay. "Jacob's unique combination of deep technological and commercial experience will be a great addition to Illumina," Stephen MacMillan, the chair of Illumina's board, said in the release. Thaysen will take over for Charles Dadswell, who has been serving as Illumina's interim CEO since June.

Persons: Illumina, Jacob Thaysen, Carl Icahn, Francis deSouza, Icahn, Thaysen, Stephen MacMillan, Charles Dadswell, Dadswell Organizations: Union, European Commission, U.S . Federal Trade Commission, Illumina Locations: Illumina, San Diego , California, U.S, Agilent

REUTERS/Mike Blake/File PhotoCompanies Grail Inc FollowIllumina Inc FollowAug 11 (Reuters) - The U.S. Securities and Exchange Commission (SEC) has begun an investigation into Illumina's (ILMN.O) $7.1 billion acquisition of cancer detection test maker Grail (GRAL.O), the gene sequencing company said in a regulatory filing. An SEC spokesperson said the agency "does not comment on the existence or nonexistence of a possible investigation". Illumina declined to comment or provide further details on the SEC investigation. The gene-sequencing machine maker had repurchased Grail in 2021, despite opposition from U.S. and European antitrust regulators, a decision that prompted investor Carl Icahn to pursue a proxy fight at Illumina, arguing Grail should be divested as it had cost investors billions of dollars. Illumina was fined 432 million euros ($476 million) by the EU last month for closing the deal before approval by European antitrust regulators.

Persons: Mike Blake, Illumina, Carl Icahn, Mariam Sunny, Shounak Dasgupta Organizations: REUTERS, U.S . Securities, Exchange Commission, SEC, EU, Thomson Locations: San Diego , California, U.S, California, Illumina, Bengaluru

☆ SEC investigating Illumina over acquisition of cancer test developer Grail
▼ + stars: | 2023-08-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail, the DNA sequencing company said in a securities filing late Thursday. Last month, the SEC informed Illumina about the probe and requested documents and communications related to the deal. The company's market value has fallen to roughly $28 billion from around $75 billion the month the deal closed. Illumina's Grail deal has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union. The European Commission, the EU's executive body, fined Illumina a record $476 million last month for closing the acquisition without first securing regulatory approval.

Persons: Illumina, That's, Carl Icahn Organizations: The Securities, Exchange Commission, SEC, Union, The European Commission, Illumina, U.S . Federal Trade Commission Locations: Illumina, San Diego , California, U.S

☆ Cramer's Lightning Round: KeyCorp is a buy
▼ + stars: | 2023-07-20 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon Illumina's year-to-date stock portfolio. Stock Chart Icon Stock chart icon Compass Pathways' year-to-date stock performance. Stock Chart Icon Stock chart icon KeyCorp's year-to-date stock performance. Stock Chart Icon Stock chart icon Eaton's year-to-date stock performance. Stock Chart Icon Stock chart icon ASML Holding's year-to-date stock performance.

Persons: Eaton, you've, ASML Organizations: Verve Therapeutics, ASML, Taiwan Semi Locations: Informatica, Taiwan

[1/2] The sun sets behind the U.S. Capitol dome in Washington, U.S., on midterm election day, November 6, 2018. It was not the first loss for the agency under Khan. In addition, an internal FTC judge ruled for Illumina's (ILMN.O) purchase of Grail (GRAL.O). Lawmakers are also expected to bring up the committee's requests for documents regarding the agency's review of billionaire Elon Musk's purchase of Twitter. Conservatives have accused social media companies, including Twitter before it was acquired by Musk, of seeking to stifle conservative voices.

Persons: James Lawler Duggan, Lina Khan, Jim Jordan, Trump, Black Knight, Amgen's, Elon Musk's, Diane Bartz, Matthew Lewis Organizations: U.S, Capitol, REUTERS, WASHINGTON, U.S . Federal Trade Commission, Republican, Committee, FTC, Microsoft, Activision, Khan, Facebook, Illumina's, Black, Horizon Therapeutics, Twitter, Musk, Thomson Locations: Washington , U.S, Washington

☆ Illumina hit with record $476 million EU antitrust fine over Grail deal
▼ + stars: | 2023-07-12 | by ( Foo Yun Chee | ) www.reuters.com time to read: +3 min

SummaryCompanies Fine corresponds to 10% of Illumina global turnoverGrail given symbolic 1,000-euro fine for active roleIllumina says fine disproportionate, will appealBRUSSELS, July 12 (Reuters) - U.S. genetic testing company Illumina (ILMN.O) was fined a record 432-million-euro ($476 million) by the EU on Wednesday for closing its takeover of cancer test maker Grail (GRAL.O) before securing EU antitrust approval. By closing the deal prematurely, Illumina was able to exercise a decisive influence over Grail, the EU enforcer said, calling the move unprecedented and a very serious infringement. Illumina and Grail knowingly and deliberately did so by implementing their tie-up as we were still investigating," EU antitrust chief Margrethe Vestager said in a statement. The company has challenged the EU veto of the deal, its decision to examine the deal despite not meeting the EU merger criteria and the EU order to keep Grail separate so that it can unwind the deal. It said success in the second case would nullify the EU fine and expects the EU court to rule in late 2023 or early 2024.

Persons: Illumina, Margrethe Vestager, Grail, Ilumina, Foo Yun Chee, Elaine Hardcastle Organizations: EU, European Commission, Regulators, U.S . Federal Trade Commission, Thomson Locations: BRUSSELS, U.S, EU

☆ Illumina hit with record $476 million fine for closing Grail deal without EU approval
▼ + stars: | 2023-07-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

European Union regulators on Wednesday fined Illumina a record 432 million euros ($476 million) for closing its acquisition of cancer test developer Grail without first securing regulatory approval. The fine from the European Commission, the EU's executive body, amounts to 10% of San Diego-based Illumina's turnover. The Illumina fine exceeds the commission's previous largest merger regulation fine of $125 million, or 1% of annual turnover, imposed on telecommunications company Altice in 2018. Illumina has already put aside $453 million to cover a potential maximum fine of 10% of turnover, according to a regulatory filing from earlier this year. "This is a very serious infringement, which requires the imposition of a proportionate fine, with the aim of deterring such conduct," the European Commission continued.

Persons: Illumina Organizations: European Commission, EU, Altice Locations: San Diego, Menlo Park , California

☆ Factbox: What's next after US judge rules in favor of Microsoft-Activision deal?
▼ + stars: | 2023-07-11 | by ( ) www.reuters.com time to read: +1 min

With the first fight in federal court in California wrapped up, the agency and companies have decisions to make about what comes next. * Or the agency may choose to challenge Corley's ruling in a federal appeals court. An administrative law judge at the FTC is scheduled to hear arguments about the deal in August. The next stop after that would be a federal appeals court. * If the FTC wins, the companies can appeal to the commission to overturn the decision and, if needed, take the case to a federal appeals court.

Persons: Jacqueline Scott Corley, Corley's, Michael Chappell, Lina Khan, Chappell, Khan, Diane Bartz, Matthew Lewis, David Gregorio Our Organizations: Microsoft, Activision, U.S . Federal Trade Commission, Meta, FTC, Thomson Locations: California, Illumina's, Washington

NEW YORK/LONDON, June 30 (Reuters) - Global mergers and acquisitions (M&A) activity fell 36% year-on-year in the second quarter, but investment bankers and lawyers expressed optimism that the stock market's recovery will gradually restore chief executives' dealmaking confidence. "Global uncertainty is what is impacting M&A most - it just makes people uncomfortable. It's easier to say, I'll pass on a deal - nobody gets fired for passing on a deal. M&A volumes in the United States declined by 30% to $318.4 billion, while Europe and Asia Pacific volumes shrank 49% and 24% respectively. Not a single so-called mega-deal, which typically refers to transactions worth over $25 billion, was signed during the quarter.

Persons: Michael Aiello, Weil, Raymond McGuire, Steve Baronoff, Bunge, John Collins, Morgan Stanley, there’ll, Ethan Klingsberg, Deringer, Manolo Falco, Scott Miller, Sullivan, Cromwell, Howard Ellin, Flom, Dwayne Lysaght, Eric Schiele, Kirkland, Ellis, Anirban Sen, Andres Gonzalez, Stephen Coates Organizations: Manges LLP, Lazard Ltd, Bank of America, Reuters Graphics Reuters, Magellan Midstream Partners, Viterra Ltd, Carrier Global, Investment, Citigroup Inc, JPMorgan Chase, Antitrust, U.S . Federal Trade Commission, Horizon Therapeutics, Thomson Locations: United, Europe, Asia, Skadden, Slate, New York, London

☆ Illumina starts job cuts, plans office exit to rein in costs
▼ + stars: | 2023-06-26 | by ( ) www.reuters.com time to read: +1 min

Illumina has begun to lay off 10% of its research and development team, health news website STAT reported on Monday, citing internal emails. Illumina, which had engaged in a proxy battle with activist investor Carl Icahn, earlier this month said CEO Francis deSouza had stepped down. The reduction in workforce commenced on June 21 and will result in charges of about $25 to $35 million, the company said, with majority incurred in the second quarter. Illumina's core global workforce comprised about 10,200 full-time employees as of Jan. 1, according to a regulatory filing. Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila and Maju SamuelOur Standards: The Thomson Reuters Trust Principles.

Persons: Illumina, Carl Icahn, Francis deSouza, Khushi, Sriraj Kalluvila, Maju Samuel Organizations: Illumina, Thomson Locations: California, Bengaluru

☆ Factbox: Potential outcomes of FTC legal bids to block Microsoft-Activision deal
▼ + stars: | 2023-06-16 | by ( ) www.reuters.com time to read: +2 min

The first fight will be in federal court in California, beginning on June 22 and running until June 29. Here are four potential outcomes of the California hearing:* Judge Jacqueline Scott Corley may grant the preliminary injunction and the companies terminate. The FTC lost in federal court and dropped the internal FTC challenge. That can be appealed to a federal appeals court. The next stop after that would be a federal appeals court.

Persons: Jacqueline Scott Corley, Corley, Michael Chappell, Lina Khan, Chappell, Khan, Diane Bartz, Matthew Lewis Organizations: Microsoft, Activision, DirecTV, Federal Trade Commission, FTC, Meta, Thomson Locations: California, Illumina's, Washington

☆ Illumina acquisition of Grail wins support from GOP lawmakers, state AGs as FTC tries to block it
▼ + stars: | 2023-06-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Republican lawmakers, state attorneys general and several advocacy groups have voiced their support for Illumina's acquisition of cancer-test developer Grail while the Federal Trade Commission fights to unwind the deal. The groups filed 14 amicus briefs Monday urging the U.S. 5th Circuit Court of Appeals to reverse an FTC order that would have Illumina undo the $7.1 billion Grail deal over concerns that it stifles competition. Thirty-four Republican lawmakers touted Grail's early screening test, which can detect more than 50 types of cancers through a single blood draw. And activist investor Carl Icahn, who holds a 1.4% stake in Illumina, launched a proxy fight with the company over the Grail deal. Icahn's opposition stemmed from Illumina's decision to close the acquisition without first gaining approval from antitrust regulators.

Persons: Illumina, Carl Icahn, Francis deSouza Organizations: Federal Trade Commission, U.S, FTC, Food and Drug Administration, European Commission Locations: San Diego, Alaska , Arkansas, Georgia , Idaho , Indiana , Iowa , Kentucky, Louisiana , Nebraska, South Carolina , Utah, Virginia, Illumina

☆ Illumina announces CEO transition plan as Francis deSouza resigns
▼ + stars: | 2023-06-11 | by ( Ashley Capoot | ) www.cnbc.com time to read: +1 min

Illumina on Sunday announced its board of directors has accepted the resignation of CEO Francis deSouza, just weeks after activist investor Carl Icahn failed to oust him from the biotech company. "It has been the privilege of a lifetime to serve Illumina," deSouza said in the release. Similarly, in an open letter to Illumina shareholders in April, Icahn accused deSouza of "desperately, hilariously and, most of all, unsuccessfully" trying to spin "decidedly mediocre" quarterly results during a press tour. In late May, Icahn had urged shareholders to vote off deSouza and Chairman John Thompson from the nine-member board. Shareholders booted Thompson, but deSouza held onto his role until Sunday.

Persons: Francis deSouza, Illumina, Carl Icahn, Charles Dadswell, Illumina's, DeSouza's, deSouza, Icahn, John Thompson, Thompson Organizations: Illumina Inc, Economic, Sunday Locations: Davos, Switzerland, Illumina

REUTERS/Mike Blake/File PhotoWASHINGTON, June 5 (Reuters) - Illumina (ILMN.O) on Monday filed an appeal against a Federal Trade Commission (FTC) order, demanding that it divest cancer diagnostic test maker Grail (GRAL.O) over competition concerns in the U.S. market for cancer tests. San Diego-based Illumina is arguing that the FTC "violated due process by depriving Illumina and Grail of a fair proceeding before an impartial tribunal," according to the filing in the U.S. Fifth Circuit Court of Appeals. An administrative law judge at the FTC had earlier dismissed the antitrust charges brought against Illumina but FTC staff won an appeal against that decision. In early December, EU antitrust regulators proposed measures for Illumina to unwind its acquisition of Grail, three months after blocking the deal. Billionaire investor Carl Icahn, who owns 1.4% of the company, had also urged Illumina to unwind the Grail deal which he called a risky acquisition.

Persons: Mike Blake, Illumina, Carl Icahn, Francis deSouza, Vincent Intrieri, Diane Bartz, Mrinmay Dey, Jamie Freed, Edwina Gibbs Organizations: REUTERS, WASHINGTON, Federal Trade Commission, Fifth, Appeals, FTC, Illumina, Thomson Locations: San Diego , California, U.S, Diego, Europe, EU

☆ Illumina board appoints Hologic CEO as non-exec chairman
▼ + stars: | 2023-06-02 | by ( ) www.reuters.com time to read: 1 min

June 2 (Reuters) - Illumina Inc (ILMN.O) said on Friday it had elected two new independent board members, including Hologic Inc (HOLX.O) CEO Stephen MacMillan as the non-executive chairperson, with immediate effect. The genetic sequencing equipment maker also appointed Edwards Lifesciences (EW.N) Chief Financial Officer Scott B. Ullem to the board, the company said in a statement. These appointments follow activist investor Carl Icahn mustering enough shareholder support last month to oust Illumina's board chair John Thompson and install one of his board nominees, Andrew Teno. However, Illumina CEO Francis deSouza survived a challenge to his board seat from Icahn. Reporting by Leroy Leo in Bengaluru; Editing by Savio D'Souza and Rashmi AichOur Standards: The Thomson Reuters Trust Principles.

Persons: Stephen MacMillan, Edwards Lifesciences, Scott B, Ullem, Carl Icahn, Illumina's, John Thompson, Andrew Teno, Francis deSouza, Leroy Leo, Savio D'Souza, Rashmi Organizations: Illumina, Hologic Inc, Thomson Locations: Icahn, Bengaluru

☆ Illumina shareholders oust board chair, CEO survives Carl Icahn proxy battle
▼ + stars: | 2023-05-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Activist investor Carl Icahn on Thursday won enough support from Illumina shareholders to oust the biotech company's board chair. Icahn had urged shareholders to vote off the company's CEO, Francis deSouza, and Thompson from the nine-member board. Shareholders also voted to install one of Icahn's three board nominees, Andrew Teno, a portfolio manager at Icahn Capital LP, an entity where Icahn manages investment funds. Earlier this month, proxy advisory firm Institutional Shareholder Services recommended that Illumina shareholders back Teno. Icahn, who owns a 1.4% stake in San Diego-based Illumina, had proposed two other director candidates who are his current or former employees.

☆ Carl Icahn calls Illumina Q1 results ‘very disappointing,’ slams cost-cutting plan
▼ + stars: | 2023-04-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Carl Icahn on Friday called Illumina's first-quarter results "very disappointing" and slammed the DNA sequencing company's new plans to cut costs. "Illumina CEO Francis deSouza seems to believe that he can fool all of the people all of the time," Icahn wrote. Illumina's stock is down more than 9% since the company reported earnings. In that missive, Icahn also took shots at cost-cutting plans Illumina unveiled to improve its shrinking margins. Illumina reported a negative operating margin of 5.7% for the quarter, down from 15% during the same period a year ago.

☆ Illumina CEO touts Grail’s 100% revenue growth amid proxy fight with Icahn
▼ + stars: | 2023-04-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Illumina CEO Francis deSouza on Wednesday touted the company's controversial acquisition of Grail after revenue from the cancer test developer doubled in the last year. The Grail deal is the focus of a heated proxy fight between Illumina and activist investor Carl Icahn. Antitrust regulators in the U.S. and Europe have also ordered Illumina to divest the $7.1 billion acquisition Illumina completed in 2021. He added that the Grail deal "makes sense" for Illumina because the company can significantly expand the market for the test. But Icahn, who owns a 1.4% stake in Illumina, has called the Grail deal "disastrous" and "a new low in corporate governance."

Search resuls for: "Illumina's"

25 mentions found